Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Charles River Laboratories International, Inc. (CRL) vs Revvity Inc. (RVTY)

Charles River Laboratories International, Inc. and Revvity Inc. are both Diagnostics & Research companies. Revvity Inc. is the larger, with a market value of $16.8B against $14.1B — 1.2× the size. Charles River Laboratories International, Inc. has negative trailing earnings, so its P/E is not meaningful; Revvity Inc. trades at 72.0×. Revvity Inc. grew revenue faster over the last twelve months: 4.05% against −0.74%. Revvity Inc. has the higher net margin (8.16% vs −5.96%) and the higher return on invested capital (2.38% vs 1.07%). Across the 21 metrics below, Revvity Inc. leads on 17 and Charles River Laboratories International, Inc. on 4.

Valuation

Metric CRL RVTY Diagnostics & Research median
P/E n/m 71.96 33.95
P/S 3.52 5.79 4.87
P/B 4.94 2.33 3.12
Price to free cash flow 37.94 29.84 34.02
EV/EBITDA 29.82 24.55 25.20
EV/Sales 4.12 6.54 5.66
Earnings yield (1.65%) 1.39% (1.75%)
Free cash flow yield 2.64% 3.35% (0.13%)

Profitability

Metric CRL RVTY Diagnostics & Research median
Gross margin 32.67% 54.98% 50.89%
Operating margin 2.25% 12.32% (8.57%)
Net margin (5.96%) 8.16% (6.37%)
Free cash flow margin 9.27% 19.58% 0.00%
Return on equity (7.69%) 3.21% (2.92%)
Return on assets (3.16%) 1.95% (6.71%)
Return on invested capital 1.07% 2.38% 0.00%

Growth

Metric CRL RVTY Diagnostics & Research median
Revenue growth (TTM) (0.74%) 4.05% 7.69%
EPS growth (last fiscal year) (1,555.00%) (5.91%) —
Revenue growth, 5-year CAGR 6.55% 1.41% 7.40%
Net income growth, 5-year CAGR 0.00% (19.82%) 0.00%

Health

Metric CRL RVTY Diagnostics & Research median
Debt to equity 0.92 0.44 0.11
Current ratio 1.35 1.80 2.02
Net debt to EBITDA 3.24 3.00 0.78

Dividend

Metric CRL RVTY Diagnostics & Research median
Dividend yield — 0.27% 0.70%
Payout ratio 0.00 0.05 0.00

Size

Metric CRL RVTY Diagnostics & Research median
Market cap 14.09b 16.81b 2.56b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack